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Immunoglobulin E (IgE) antibodies play a central role in the allergic response: interaction with FcεRI 
on mast cells and basophils leads to immediate hypersensitivity reactions upon allergen challenge, 
while interaction with CD23/FcεRII, expressed on a variety of cells, regulates IgE synthesis among other 
activities. The receptor-binding IgE-Fc region has recently been found to display remarkable flexibility, 
from acutely bent to extended conformations, with allosteric communication between the distant 
FcεRI and CD23 binding sites. We report the structure of an anti-IgE antibody Fab (8D6) bound to IgE-Fc 
through a mixed protein-carbohydrate epitope, revealing further flexibility and a novel extended 
conformation with potential relevance to that of membrane-bound IgE in the B cell receptor for antigen. 
Unlike the earlier, clinically approved anti-IgE antibody omalizumab, 8D6 inhibits binding to FcεRI 
but not CD23; the structure reveals how this discrimination is achieved through both orthosteric and 
allosteric mechanisms, supporting therapeutic strategies that retain the benefits of CD23 binding.
The interactions between immunoglobulin E (IgE) and its two receptors, FcεRI and CD23 (FcεRII), play pivotal 
roles in allergic disease1,2. FcεRI is principally expressed on the surface of mast cells and basophils. Allergen 
mediated cross-linking of FcεRI-bound IgE on the surface of these IgE-sensitized cells triggers degranulation and 
release of inflammatory mediators1,2. CD23 is expressed in membrane-bound (mCD23) and soluble forms, the 
latter existing as monomeric or trimeric fragments1,3–5. CD23, expressed on B cells and a range of other cell types, 
regulates a diverse set of immunological functions, including cellular adhesion, antigen presentation, regulation 
of growth and differentiation of B and T cells, rescue from apoptosis, release of cytotoxic and inflammatory 
mediators, transcytosis of IgE-immune complexes, and regulation of IgE synthesis1,3–5. CD23-deficient mice or 
those strains carrying mutated CD23 variants show a hyper-IgE phenotype6–8 whereas transgenic strains that 
overexpress CD23 show reduced levels of IgE9,10. Moreover, B cells, rather than FcεRI-bearing cells, are the major 
cell type controlling serum IgE levels in a CD23-dependent manner11.
IgE-Fc, the region of the antibody responsible for effector functions, comprises two identical chains, each 
composed of three immunoglobulin-like domains: Cε2, Cε3 and Cε4. IgE, and IgE-Fc, adopt a compact, bent 
structure in solution12–18, and the crystal structure of IgE-Fc revealed an acutely bent conformation, in which 
the (Cε2)2 domain pair folds back against the Fcε3-4 region, with an angle of 62° between the local two-fold axes 
of the (Cε2)2 domain pair and Cε4 domains19,20. Crystal structures of unliganded and receptor-bound forms 
of IgE-Fc, and the Fcε3-4 region, reveal the Cε3 domains to adopt a range of “open” and “closed” orientations 
relative to the Cε4 domain pair19–29. The interaction between IgE-Fc and FcεRIα involves an “opening” of the 
Cε3 domains, which engage FcεRI at two distinct sub-sites on the Cε2-proximal region of each Cε3 domain19,25, 
and IgE-Fc becomes even more acutely bent (54°) in the receptor-bound complex12,19. CD23 engages IgE-Fc at a 
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region of the Cε3 domain distal to the FcεRIα binding site, and near the interface with the Cε4 domain22,23,28,29. 
Crystal structures of IgE-Fc and the Fcε3-4 region in complex with CD23 reveal this receptor to engage a range of 
“closed” Cε3 domain conformations22,23,28,29. The open and closed Cε3 domain conformations involved in FcεRIα 
and CD23 interactions, respectively, preclude simultaneous engagement of both receptors by IgE-Fc; binding of 
FcεRIα and CD23 are thus regulated in an allosteric manner22,23,29,30.
Unexpectedly, IgE-Fc was recently observed to undergo a large-scale conformational change24. An anti-IgE-Fc 
Fab (aεFab) captured IgE-Fc in an extended conformation, and the crystal structure of the aεFab/IgE-Fc com-
plex revealed a fully extended, linear IgE-Fc molecule, in which the local two-fold axes of the Cε2, Cε3 and Cε4 
domain pairs were coincident, and the (Cε2)2 domain pair no longer contacted the Fcε3-4 region24. This extreme 
conformational flexibility is suggested to underpin the different biological functions of IgE, with acutely bent 
FcεRI-bound IgE positioning the Fabs in an appropriate orientation for cross-linking by allergen, and the fully 
extended molecule, in the membrane-bound form (mIgE) as part of the B-cell receptor for antigen, extending the 
Fabs away from the membrane, to facilitate antigen capture24.
The interaction between IgE and FcεRI is a long-standing target in the treatment of allergic disease2. The 
therapeutic monoclonal anti-IgE antibody omalizumab (Xolair®, Novartis) is approved for the treatment of 
moderate-to-severe persistent allergic asthma and chronic idiopathic urticaria31,32. Omalizumab prevents IgE 
from engaging both FcεRI and CD23, decreases serum IgE levels in vivo by up to 95% and down-regulates sur-
face expression of FcεRI on basophils31,33–35. The structural basis for the mechanism of action of omalizumab has 
recently been elucidated36; omalizumab inhibits the binding of IgE to FcεRI allosterically, as antibody binding 
causes the Cε3 domains to adopt a conformation that is too open to permit simultaneous engagement of both 
FcεRI sub-sites on IgE-Fc36, while the binding of IgE to CD23 is inhibited orthosterically36,37. Another anti-IgE 
antibody, MEDI4212, also inhibits the interaction between IgE-Fc and its two receptors21; binding to FcεRI is 
inhibited due to steric overlap, while binding to CD23 is inhibited as the Cε3 domains are “locked” in an open 
conformation21.
A large body of literature supports roles for CD23 both as an essential regulatory molecule in normal immune 
responses, and as a marker of, and mediator in, the pathophysiology of a number of human disorders. A pri-
matized anti-CD23 antibody, lumiliximab/IDEC-152, showed modest clinical efficacy in early clinical trials for 
allergic asthma, where it reduced circulating IgE levels by about 40% during the period of active treatment38,39, 
but was not taken forward into late clinical trials. Indeed, there may be advantages to a therapeutic strategy that 
combines IgE neutralization and modulation of IgE production simultaneously.
8D6 is a monoclonal anti-IgE antibody that, like omalizumab and MEDI4212, inhibits the interaction between 
IgE and FcεRI33, thus preventing mast cell degranulation. However, 8D6, and 8D6/IgE-immune complexes, are 
able to engage IgE that is already bound to mCD23 on B cells33. An antibody with the binding characteristics of 
8D6 could thus exploit the ability of CD23 to down-regulate IgE production, such as cross-linking of mCD23 by 
IgE-immune complexes, which inhibits B-cell proliferation and IgE synthesis40,41.
Here we report the 3.7 Å resolution crystal structure of IgE-Fc in complex with two 8D6 Fab fragments. IgE-Fc 
adopts a nearly linear conformation, exposing both faces of the Fcε3-4 region, to which the Fabs bind through a 
mixed protein-carbohydrate epitope. This extended IgE-Fc conformation is more compact than the conformation 
captured by aεFab24, with the (Cε2)2 domain pair instead contacting the Cε3 domains. The more compact IgE-Fc 
molecule demonstrates that not only is IgE dynamic, with the ability to flex from an acutely bent to an extended 
structure24, but the fully extended molecule itself is also conformationally diverse.
The structure of the 8D6 Fab/IgE-Fc complex reveals that FcεRI binding is inhibited both allosterically and 
orthosterically. By contrast, the CD23 binding site is accessible, and solution studies demonstrate that the affinity 
of IgE-Fc for CD23 is not substantially altered when in complex with 8D6. We thus reveal the structural basis by 
which IgE-Fc binding to its two principal receptors can be selectively modulated, offering insights into an alter-
native therapeutic approach to the treatment of allergic disease.
Results
Affinity of the 8D6 Fab for IgE-Fc. We performed SPR-based molecular interaction studies to measure 
binding stoichiometry, kinetics and affinities for the interaction of the 8D6 Fab with IgE-Fc. The 8D6 Fab was 
covalently coupled to an SPR sensor chip using a standard amine coupling protocol. IgE-Fc, over a range of 
concentrations, was flowed over the 8D6 surface, and association and dissociation rate constants were extracted 
from the binding curves (Supplementary Fig. S1). At the highest concentrations tested there was evidence for two 
distinct binding events, but at low and intermediate concentrations the interaction is well described as having a 
KD of about 20 pM, with kon = 5 × 106 M−1 s−1 and koff = 8 × 10−5 s−1, where the slow dissociation rate is the main 
contributor to the high affinity interaction.
The homodimeric character of IgE commonly results in two separate epitopes for anti-IgE antibodies and the 
asymmetrical structure of IgE-Fc sometimes results in two different affinities for the two epitopes24,36. To identify 
and characterize the binding of a second 8D6 Fab, we captured IgE-Fc on an 8D6 Fab sensor surface, and then 
measured the binding of a second 8D6 Fab to the IgE-Fc/8D6 Fab complex (Supplementary Fig. S1). Although 
slightly weaker than the first binding site, the second 8D6 Fab interaction is still high affinity, with a KD of about 
60 pM (kon = 1 × 106 M−1 s−1, koff = 6 × 10−5 s−1). These SPR-based interaction analyses confirmed the expected 
2:1 stoichiometry of 8D6 for IgE, and showed that both sites have subnanomolar binding affinities, which are 
higher than those for the clinically approved omalizumab36.
Overall structure of the 8D6 Fab/IgE-Fc complex. We solved the crystal structure of the 8D6 Fab/
IgE-Fc complex, in which two 8D6 Fab fragments are bound to IgE-Fc, at 3.7 Å resolution. IgE-Fc adopts a 
fully extended conformation, exposing both faces of the Fcε3-4 region, to which the 8D6 Fabs bind (Fig. 1a,b, 
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Supplementary Movie S1). Each 8D6 Fab binds across both Cε3 domains, and forms a minor interface with one 
Cε2 domain, but there is no contact with the Cε4 domains.
The extended IgE-Fc conformation is more compact in the 8D6 Fab/IgE-Fc complex. The 
two-fold axes of the IgE-Fc Cε2, Cε3 and Cε4 domain pairs are coincident in the extended IgE-Fc molecule within 
the 8D6 Fab/IgE-Fc complex, resembling those in the fully extended conformation captured by aεFab24 (Fig. 2). 
However, further comparison of these complexes reveals substantial differences in the overall structure of IgE-Fc. 
In the aεFab/IgE-Fc complex, the (Cε2)2 domain pair is positioned too far away from the Cε3 domains to form 
any significant contacts. By contrast, in the 8D6 Fab/IgE-Fc complex, the Cε2 domain contacts the Cε3 domain 
from the same chain (Fig. 2a,b, Supplementary Fig. S2). Furthermore, the overall position of the (Cε2)2 domain 
pair relative to the Cε3 and Cε4 domains differs in the two complexes by a relative rotation of ~30° about the local 
two-fold axis (Fig. 2g,h). A spiral motion, resembling a corkscrew, is required to overlay the (Cε2)2 domain pair 
from the two structures, in which the (Cε2)2 domain pair and Cε2-Cε3 domain linker move as a rigid unit relative 
to the Cε3 domains (Movie S2). The overall length of the fully extended IgE-Fc molecule is ~3 Å shorter in the 
8D6 Fab/IgE-Fc complex, which is thus more compact (Fig. 2a,b).
As the two IgE-Fc chains are not perfectly symmetrical in the 8D6 Fab/IgE-Fc complex, the interface between 
the Cε2 and Cε3 domains differs in each chain. In chain A, Leu305, Ser306 and Asp307 from the Cε2 domain 
form a 70 Å2 interface with Cε3 domain FG loop residues Pro423, His424 and Pro426, with Ser306, Asp307 and 
His424 contributing the largest contact area (Supplementary Fig. S2). The same residues contact one another in 
chain B, but form a larger interface of 113 Å2, with a more substantial contribution from Pro426.
In IgE-Fc and Fcε3-4 crystal structures, the Cε3 domains adopt a range of positions relative to the Cε4 
domains, from “closed” to “open”19–29,36. The Cε3 domains adopt a more “closed” conformation in the 8D6 Fab/
IgE-Fc complex compared with their position in the aεFab/IgE-Fc complex24 (Fig. 2c–f, Supplementary Fig. S3); 
this closed conformation is comparable with the range of closed conformations observed in CD23/Fcε3-4 com-
plex crystal structures22,23,28,29, and is consistent with the ability of 8D6-bound IgE to bind CD2333.
Cε3 domain flexibility. In addition to the variability observed for the relative domain orientations, the 
Cε3 domain has also been shown to possess significant intra-domain mobility; indeed the isolated Cε3 domain 
has molten-globule-like characteristics42,43. In the interaction between IgE-Fc and FcεRI, the Cε3 domain BC, 
C’E and FG loops play a critical role19,25. A comparison of the Cε3 domains in IgE-Fc and Fcε3-4 crystal struc-
tures19–29,36,37,44,45 reveals that the BC loop (residues 363 to 370) adopts a variety of conformations (Supplementary 
Fig. S4), or is partially disordered. The ordered conformations are such that the positions of certain side chains, 
Figure 1. Overall structure. (a) Two 8D6 Fabs (light green and light pink) bind to IgE-Fc (blue and yellow) 
in the 8D6Fab/IgE-Fc complex, which adopts an extended conformation. (b) 8D6 binds the exposed face of 
the Fcε3-4 region. Each 8D6 Fab binds across the Cε3 domains, and forms a minor interface with one Cε2 
domain [shown in a], but does not contact the Cε4 domains. The 8D6 heavy chain (light green and light pink) 
contributes the largest area of interaction. For clarity, the (Cε2)2 domain pair is not shown.
www.nature.com/scientificreports/
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Figure 2. Fully extended forms of IgE-Fc. (a) Overall structure of IgE-Fc in the aεFab/IgE-Fc complex24. IgE-Fc 
chains A and B are coloured blue and green, respectively. (b) Overall structure of IgE-Fc in the 8D6 Fab/IgE-Fc 
complex. IgE-Fc chains A and B are coloured yellow and pink, respectively. (c) “Top” view of the Cε3 domains 
in the aεFab/IgE-Fc complex24. (d) “Top” view of the Cε3 domains in the 8D6 Fab/IgE-Fc complex. (e) Fcε3-4 
domains in the aεFab/IgE-Fc complex. (f) Fcε3-4 domains in the 8D6 Fab/IgE-Fc complex. The arrows indicate 
that the domains adopt a more closed conformation. (g) (Cε2)2 domain pair position in the aεFab/IgE-Fc 
complex24. The curved arrow indicates that the (Cε2)2 domain pair rotates to generate the position observed in 
the 8D6 Fab/IgE-Fc complex, shown in h. (h) (Cε2)2 domain pair position in the 8D6 Fab/IgE-Fc complex.
www.nature.com/scientificreports/
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such as Lys367, are significantly altered in different structures. Lys367 is surface exposed in the BC loop confor-
mations found in free IgE-Fc19,20 and Fcε3-426,27, FcεRIα-bound IgE-Fc and Fcε3-419,25, and CD23-bound IgE-Fc 
and Fcε3-422,23,28,29, and its side chain extends away from the Cε3 domain. In the aεFab/IgE-Fc complex24, the 
Lys367 side chain rests across the β-sandwich in a groove created by the Glu389, Lys391 and Leu397 side chains, 
and lies at one edge of the interface between IgE-Fc and the Fab. By contrast, Lys367 in the 8D6 Fab/IgE-Fc com-
plex is wedged between the two sheets of the Cε3 β-sandwich, partially enclosed in a pocket created by Leu363, 
Ala364, Val370 (BC loop), His422, His424 and Leu425 (FG loop) (Supplementary Fig. S4). This conformation, 
which has not been observed in any other IgE-Fc or Fcε3-4 structure thus far, causes the C’E and FG loops to 
splay apart (Supplementary Fig. S4), and in chain B, brings Lys367 within contact distance of Asn332 (Cε2-Cε3 
domain linker) in chain A (Supplementary Fig. S4). (Due to the asymmetry in IgE-Fc in the complex, Lys367 in 
chain A is positioned slightly further away from Asn332 in chain B).
In the 8D6 Fab/IgE-Fc complex, the BC loop forms part of the interface with CDRH1 and 3 from the Fab; BC 
loop conformations found in other structures are incompatible with the 8D6 Fab interface due to steric clashes. 
We cannot determine whether the Cε3 BC loop conformation found in the 8D6 Fab/IgE-Fc complex is induced 
or selected by the 8D6 Fab. Nevertheless, this structure provides further insights into the dynamic nature of the 
Cε3 domain, and suggests a potential role for the BC loop in the allosteric communication network in IgE-Fc that 
allows local conformational changes to contribute to global structural changes.
8D6 binds a mixed protein-carbohydrate epitope. Approximately two-thirds of the 1150 Å2 interface 
with IgE-Fc is contributed by the 8D6 heavy chain, which contacts the Cε2 and Cε3 domains from one IgE-Fc 
chain, and the Cε2-Cε3 domain linker from the other IgE-Fc chain. The interface between the heavy chain and 
Cε3 domain, covering an area of ~640 Å2, is similar for each Fab, and includes residues from the Cε3 domain B, 
C’ and E strands, and BC, C’E and FG loops. Notably, Trp33 (CDRH1) is sandwiched between the Pro365 and 
Lys391 (Cε3) side chains, and the interface also includes a number of hydrogen bonds (Fig. 3a). The interface 
with the Cε2 domain covers an area of ~140 Å2, in which Tyr27 and Phe29 (CDRH1) pack against Gln301, Lys302 
and Leu305 (Cε2). Although the two IgE-Fc chains are not identical, similar contacts are maintained between 
the heavy chain and Cε2 domain at each interface; main chain atoms for residues Gly26-Phe29 (CDRH1) shift 
to preserve this interaction, for example, the Tyr27 Cα atom position differs by 1.5 Å (Supplementary Fig. S5). 
Figure 3. Interface between the 8D6 Fab and IgE-Fc. (a) The Fab heavy chain (light pink) forms a 640 Å2 
interface with the Cε3 domain (blue). Trp33 (CDRH1) is sandwiched between the Pro365 and Lys391 (Cε3 
domain) side chains. (b) The Fab heavy chain (green) engages the Cε2 and Cε3 domains from one IgE-Fc chain 
(yellow), but also contacts the Cε2-Cε3 linker from the other IgE-Fc chain (blue). Asn30 and Arg102 from the 
Fab are within hydrogen bonding distance of Ser331 and Asn332 (Cε2-Cε3 linker), respectively. (c) Tyr31, 
Tyr36 and Asn96 from the Fab light chain (dark pink) form a cleft around Arg393 (Cε3 domain, blue). (d) In a 
106Å2 interface, Asp32, Gly33 and Asp34 from the Fab light chain (dark pink) contact two mannose residues 
(Man906 and Man907), and Asp34 forms a hydrogen bond with the α(1-2) glycosidic bond between Man906 
and Man907.
www.nature.com/scientificreports/
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The interface with the Cε2-Cε3 linker from the other IgE-Fc chain includes a hydrogen bond between Asn30 
(CDRH1) and Ser331, and both Tyr101 and Arg102 (CDRH3) side chains are within hydrogen bonding distance 
of Asn332 (Fig. 3b).
The 8D6 Fab light chain contributes a smaller interaction area with IgE-Fc compared with the heavy chain. 
In a ~180 Å2 interface, Tyr31 (CDRL1), Tyr36 (CDRL1) and Asn96 (CDRL3) form a cleft which accommodates 
the side chain of Arg393 from the same Cε3 domain contacted by the heavy chain (Fig. 3c). The Fab light chain 
additionally, and exclusively, contacts the high-mannose oligosaccharide moiety covalently attached to Asn394 
from the other Cε3 domain. However, the nature of the light chain interaction with the carbohydrate differs for 
each Fab. For one Fab (92 Å2 interface), Asp32 and Gly33 (CDRL1) contact two mannose residues (Man906 and 
907) from the α(1–3) branch, and a hydrogen bond forms between the Asp32 main chain and the α(1–3) linked 
mannose residue, Man906. For the other Fab (106 Å2 interface), Asp32, Gly33 and Asp34 (CDRL1) contact equiv-
alent mannose residues, but a hydrogen bond forms between the Asp34 side chain and the α(1-2) glycosidic bond 
between Man906 and Man907 (Fig. 3d, Supplementary Fig. S6). Furthermore, due to the asymmetry in the 8D6/
IgE-Fc complex, residues from the C” and D strands of this Fab also form a minor interface of ~100 Å2 with the 
Cε3 domain G strand and Cε3-Cε4 domain linker. Although glycosylation at the Asn394 site is heterogeneous, we 
note that the carbohydrate units engaged by 8D6 are a core structure found in all IgE molecules46.
Conformational change in 8D6 upon IgE-Fc binding. To determine whether there were conforma-
tional changes in 8D6 upon binding to IgE-Fc, we solved the crystal structure of the 8D6 Fab at 2.4 Å resolution. 
The asymmetric unit comprises three molecules, thus providing three independent views of the uncomplexed 
Fab. With the exception of a 1-2 Å shift in the CDRH2 backbone, and some disorder in CDRH1 and CDRL1, the 
uncomplexed Fab molecules were essentially identical. However, there were significant conformational differ-
ences between unbound and complexed 8D6 Fab (Supplementary Fig. S7).
CDRH1, which is ordered in only one of the unbound 8D6 Fab structures, contacts the Cε2 domain and the 
Cε2-Cε3 linker in the 8D6 Fab/IgE-Fc complex. To form this interaction, substantial shifts occur in the positions 
of Thr28, Phe29 and Asn30 (CDRH1), but the most dramatic change occurs in the Tyr27 (CDRH1) side chain, 
which flips from one face of the main chain to the other to contact Gln301 and Lys302 from the Cε2 domain. 
Conformational flexibility in CDRH1 appears to be facilitated by the presence of two glycine residues, at positions 
26 and 31, whereas in the complex, steric constraints are imposed by the Cε3 domain residues Pro365 and Ser366 
(Supplementary Fig. S7).
Inhibition of FcεRI binding by 8D6. The high affinity interaction between IgE and FcεRI (Ka = 1010 − 
1011 M−1) involves an acutely bent conformation for IgE-Fc, in which the Cε3 domains adopt an open conforma-
tion, and engage the receptor through two distinct sub-sites1,2,19. The anti-IgE 8D6 antibody inhibits binding of 
IgE to FcεRI, and is also unable to engage FcεRI-bound IgE33. Comparison of the IgE-Fc/FcεRIα and 8D6 Fab/
IgE-Fc complexes reveals that the Cε3 domains adopt a conformation that is too closed to permit simultaneous 
engagement at both FcεRIα sub-sites (Fig. 4a). Furthermore, comparison at each sub-site of receptor engage-
ment19 reveals steric clashes between the 8D6 Fab and FcεRIα, and the (Cε2)2 domain pair and FcεRIα (Fig. 4b,c). 
Inhibition of FcεRI binding by 8D6 thus involves both allosteric and orthosteric mechanisms.
Interaction between 8D6-bound IgE-Fc and CD23. To further characterize the previously reported 
interaction between 8D6-bound IgE and CD2333 we investigated binding of fluorescently labeled IgE-Fc to 
membrane CD23 (mCD23) on RPMI 8866 cells, obviating the need for secondary IgE detection antibodies. We 
observed that IgE-Fc alone was able to bind mCD23, but failed to do so in the presence of MHM6 (anti-CD23) 
and omalizumab (anti-IgE), known inhibitors of the IgE/CD23 interaction33,47 (Fig. 5). In contrast, 8D6 did not 
inhibit IgE-Fc binding to mCD23 (Fig. 5).
We next investigated the interaction between 8D6-bound IgE-Fc and CD23 using surface plasmon reso-
nance. A soluble, monomeric CD23 construct, called derCD2348, binds to IgE-Fc captured on an 8D6 Fab sur-
face (KD = 1.7 ± 0.1 μM) with the same affinity as IgE-Fc captured via an N-terminal His-tag (KD = 1.8 ± 0.2 μM 
(Fig. 6a). This demonstrates that the 8D6 Fab, bound in a 1:1 complex with IgE-Fc, does not inhibit the interaction 
between IgE-Fc and derCD23. We also wished to determine whether a 2:1 complex between the 8D6 Fab and 
IgE-Fc would still bind CD23. We captured IgE-Fc on an 8D6 Fab surface, bound a second 8D6 Fab to this complex 
at concentrations sufficient to saturate the second binding site, and then measured binding of derCD23, over a 
range of concentrations, to the 2:1 8D6 Fab/IgE-Fc complex. We observed that binding of derCD23 to the 2:1 8D6 
Fab/IgE-Fc complex (KD = 1.7 ± 0.2 μM) was similar to binding of derCD23 to unbound IgE-Fc (KD = 1.7 ± 0.2 μM) 
(Fig. 6b). The lack of competition between 8D6 and CD23 is consistent with their distal epitopes (Fig. 6c).
CD23 binds to IgE when the Cε3 domains adopt a closed conformation; CD23 engages the Cε3 domain 
distal to the FcεRIα binding site, and the interface extends to include residues from the Cε4 domain22,23,28,29. 
Omalizumab inhibits the interaction between IgE and CD23 orthosterically36,37, while MEDI4212 (anti-IgE) 
“locks” the Cε3 domains in an open conformation, precluding the interaction with CD2321 (Supplementary 
Fig. S8). The closed Cε3 domain conformation in the 8D6 Fab/IgE-Fc complex is similar to the range of closed 
conformations observed in the eighteen independent views of the interface between CD23 and IgE-Fc and 
Fcε3–422,23,28,29, and the CD23 binding site itself is also comparable. Further structure comparison revealed no 
steric clashes between CD23 and the 8D6 Fab when chain B from the 8D6 Fab/IgE-Fc complex structure was 
compared (Fig. 6c), although minor steric clashes between CD23 and 8D6 were observed for chain A. Given that 
the interface between 8D6 and one IgE-Fc chain, mediated by the 8D6 light chain, is almost exclusively composed 
of interactions with the oligosaccharide moiety covalently attached to Asn394, and that this interface is flexible 
(Supplementary Fig. S6), it is likely that IgE-Fc could undergo a further conformational change in solution which 
would render the second binding site fully accessible.
www.nature.com/scientificreports/
7SCientifiC REPoRTS |  (2018) 8:11548  | DOI:10.1038/s41598-018-29664-4
Figure 4. Structural basis for inhibition of the interaction between IgE-Fc and FcεRI by 8D6. (a) The Cε3 
domains in the 8D6 Fab/IgE-Fc complex (light blue) adopt a closed conformation, precluding simultaneous 
engagement of both sub-sites on sFcεRIα. The 8D6 Fab/IgE-Fc complex and sFcεRIα/IgE-Fc complex (pink)19 
structures were superposed on Cε4 domain Cα atoms. (b) When the 8D6 Fab/IgE-Fc and IgE-Fc/sFcεRIα 
complex structures are superposed on the Cε3 domain which engages FcεRIα at sub-site 1, one Fab (dark blue) 
and the (Cε2)2 domain pair (light blue) from the 8D6 Fab/IgE-Fc complex clash with sFcεRIα (pink). For clarity, 
IgE-Fc from the IgE-Fc/sFcεRIα complex is not shown. (c) When the 8D6 Fab/IgE-Fc and IgE-Fc/sFcεRIα 
complex structures are superposed on the Cε3 domain which engages FcεRIα at sub-site 2, one Fab (dark blue) 
and the (Cε2)2 domain pair from the 8D6 Fab/IgE-Fc complex (light blue) clash with sFcεRIα (pink). For clarity, 
IgE-Fc from the IgE-Fc/sFcεRIα complex is not shown.
www.nature.com/scientificreports/
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Discussion
IgE-Fc adopts a predominantly bent conformation in solution12–18, and the crystal structure of IgE-Fc, alone 
and when in complex with FcεRI, is acutely bent19,20. IgE has since been discovered to be more conformationally 
dynamic than previously thought, after a fully extended conformation was unexpectedly captured in the crystal 
structure of IgE-Fc in complex with an anti-IgE Fab (aεFab)24, and a partially bent conformation, with markedly 
open Cε3 domains, was observed in the crystal structure of IgE-Fc in complex with an omalizumab-derived Fab36.
Here, we report the 3.7 Å resolution crystal structure of IgE-Fc in complex with the Fab fragment of the 
anti-IgE antibody 8D6, in which two 8D6 Fabs bind to a fully extended IgE-Fc molecule. The 8D6 Fab/IgE-Fc 
complex reveals a more compact form of fully extended IgE-Fc, in which the Cε3 domain contacts the Cε2 
domain from the same chain, and the Cε2-Cε3 domain linker from the other chain. The 8D6 Fab/IgE-Fc complex 
reveals that not only is IgE-Fc flexible, adopting both acutely bent and extended conformations, but the fully 
extended conformation itself is also conformationally diverse. A spiral motion, resembling that of a corkscrew, in 
which the Cε3 domains close, and the (Cε2)2 domain pair and Cε2-Cε3 domain linker rotate and move closer to 
the Cε3 domains, transforms one fully extended form to the other. Furthermore, the unique Cε3 BC loop confor-
mation loop conformation found in the 8D6 Fab/IgE-Fc complex suggests that local conformational changes in 
IgE-Fc contribute to global structural changes.
It remains to be determined whether the compact, extended form observed is induced, or selected, by 8D6, 
but the extended conformation previously observed in the aεFab/IgE-complex was captured by the Fab24. Given 
the potential for extreme flexibility, it is therefore possible that IgE-Fc can freely adopt this compact, extended 
conformation in solution.
In a recent molecular dynamics study exploring the unbending of IgE-Fc to an extended conformation, the 
acutely bent conformation occupied the lowest energy basin24, but the extended conformation captured by aεFab 
occupied a high-energy basin24. Given the proposed role for the extended form of IgE as part of the B-cell recep-
tor for antigen, the more compact form found in the 8D6 Fab/IgE-Fc complex provides clues about how a fully 
extended IgE conformation might be stabilized, even transiently, on the B-cell surface, to facilitate antigen capture.
Figure 5. Effect of MHM6 (anti-CD23), omalizumab (anti-IgE) and 8D6 (anti-IgE) antibodies on IgE-Fc 
binding to membrane CD23 (mCD23) on RPMI 8866 cells. IgE-Fc Alexa 647 was added to 0.5 × 106 RPMI 
8866 cells with or without MHM6, omalizumab or 8D6 at a molar ratio of 1:2 for 30 min at 4 °C. Cells were then 
washed and acquired for flow cytometry analysis. (a) Histograms show the levels of IgE-Fc bound to mCD23 on 
RPMI 8866 cells as determined by flow cytometry. (b) Summary of the mean fluorescence intensity (MFI) made 
relative to IgE-Fc Alexa 647 alone (n = 6). Statistical analysis was performed using the One-Way ANOVA, with 
Bonferroni correction. A p value of < 0.05 was considered significant (*p < 0.05,**p < 0.01,***p < 0.001).
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Figure 6. The 8D6 Fab does not prevent CD23 binding to IgE-Fc. (a) A comparison of the binding of derCD23 
to either unbound IgE-Fc (green) or an 8D6/IgE-Fc complex (purple). The binding affinity of derCD23 to 
IgE-Fc captured on an SPR sensor surface via an N-terminal His-tag was 1.6 (±0.1) μM; the binding affinity 
of derCD23 to IgE-Fc captured using the 8D6 Fab and then saturated with 8D6, to occupy both 8D6 binding 
sites on IgE-Fc, was 1.7 (±0.1) μM. (b) The binding of IgE-Fc (red) to derCD23 immobilized on an SPR sensor 
surface, was compared with the binding of a 2:1 8D6 Fab/IgE-Fc complex (blue) to the same derCD23 surface. 
SPR signal is mass dependent, so binding was normalized according to maximal binding (Bmax) in the fitted 
curve. When this normalization is done, the binding curves for unbound IgE-Fc and the IgE-Fc/8D6 Fab  
complex are nearly identical. (c) 8D6 and derCD23 bind to different sites on IgE-Fc. Comparison of the 8D6 
Fab/IgE-Fc complex and a CD23/Fcε3-4 complex22 structure reveals that there is no steric overlap between 8D6 
and CD23 in chain B of the 8D6 Fab/IgE–Fc complex. IgE-Fc chains A and B from the 8D6 Fab/IgE-Fc complex 
are coloured grey and yellow, respectively, the 8D6 Fab is coloured blue, and CD23 from the CD23/Fcε3-4 
complex22, dark pink. Structures were superposed on the Cε3 domain (chain B) from the 8D6 Fab/IgE-Fc 
complex. For clarity, the Fcε3-4 region from the CD23/Fcε3-4 complex is not shown.
www.nature.com/scientificreports/
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The interaction between IgE and FcεRI, a prerequisite for mast cell degranulation, is a long-standing target in 
the treatment of allergic disease2, and is inhibited by the clinically approved therapeutic antibody omalizumab31, 
and other anti-IgE antibodies such as MEDI421221, aεFab24 and 8D633; however, the mechanism of inhibition for 
these antibodies differs. In the complex of an omalizumab-derived Fab with IgE-Fc, the Cε3 domains adopt a 
markedly open conformation, even more open than that for FcεRI-bound IgE-Fc36, which precludes simultane-
ous engagement of the two FcεRI-binding sub-sites36, while the complex of MEDI4212 with Fcε3-4 reveals steric 
overlap with FcεRI21. In the aεFab/IgE-Fc complex, structural rearrangements in the Cε2-Cε3 domain linker, 
disruption of a key receptor interaction, and steric clashes between the extended IgE-Fc conformation and FcεRI, 
preclude receptor binding24. In the 8D6 Fab/IgE-Fc complex, the Cε3 domains adopt a conformation which is too 
closed to permit simultaneous engagement of the FcεRI-binding sub-sites, and the Cε2 domains in the extended 
IgE-Fc conformation would also clash with the receptor.
Unlike the clinically-approved omalizumab, 8D6 does not inhibit the interaction between IgE and CD2333. 
We have demonstrated here that 8D6-bound IgE-Fc binds to mCD23 on cells, and that the affinity of the 2:1 8D6/
IgE-Fc complex for a soluble fragment of CD23 (derCD23) is similar to unbound IgE-Fc. Consistent with these 
observations, the crystal structure of the 2:1 8D6 Fab/IgE-Fc complex reveals that one of the CD23 binding sites 
on IgE-Fc is fully accessible, with only minor clashes at the second site; a minor conformational change in IgE-Fc, 
involving the flexible 8D6 epitope, which includes the oligosaccharide moiety, would render the second CD23 
binding site accessible.
In its role as a regulator of IgE levels, engagement of mCD23 by IgE-immune complexes inhibits B-cell prolif-
eration and IgE synthesis3,40,41. Inhibiting the interaction between IgE and FcεRI, but not CD23, is thus a poten-
tially promising therapeutic approach in the treatment of allergic disease. Here, we have revealed the structural 
basis by which binding of IgE to these two key receptors can be selectively modulated.
Materials and Methods
Protein expression, purification and labeling. Human IgE-Fc used for the crystallographic study 
and FACS analysis, and human derCD23 used for the SPR analysis, were expressed as previously described48,49. 
Recombinant 8D6 Fab was expressed in Freestyle HEK293F cells using a previously published method50 with 
the exception that after a four hour transfection at high cell density, the cells were diluted four-fold in the pres-
ence of 3.75 mM sodium valproate, and after seven days the culture supernatant was harvested and protein puri-
fied by KappaSelect affinity chromatography. His-tagged IgE-Fc used for the SPR analysis contained the same 
sequence as that used for the crystallographic study (human IgE-Fc starting at residue Val224, with Cys225Ala, 
Asn265Gln and Asn371Gln mutations), in addition to an N-terminal tag (6xHis and Xpress tags), was expressed 
in Freestyle™ HEK293F cells, and purified by Ni2+-affinity chromatography.
The 8D6 Fab/IgE-Fc complex for the crystallographic study was purified as follows: 8D6 Fab and IgE-Fc pro-
teins were mixed at a molar ratio of 2.5:1 at 4 °C for 16 hours and the resulting complex purified by size exclusion 
chromatography using a Superdex 200 column.
For the flow cytometry analysis, IgE-Fc was concentrated to 50 µM, and dialysed overnight at 4 °C against a 
buffer of 100 mM sodium bicarbonate and 50 µM NaCl, pH 9. A 2.5 molar excess of Alexa Fluor® 647 succin-
imidyl ester (Life Technologies) was added to IgE-Fc, gently agitated for 3 hours, and then dialysed against PBS 
overnight. Absorbance of the sample at 280 nm and 647 nm was used to determine the labeling efficiency.
Surface plasmon resonance analysis. Experiments were performed on a Biacore T200 instrument (GE 
Healthcare). Specific binding surfaces were prepared by coupling 8D6 Fab to a CM5 sensor chip, using a standard 
amine coupling protocol (GE Healthcare). For measuring the affinity of the first binding site of 8D6 Fab to IgE-Fc, 
His-tagged IgE-Fc, at concentrations ranging from 100 nM to 190 pM, prepared by a 2-fold serial dilution in 
HBS-P buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.005% surfactant p20), was injected at 30 μL/min, with a 
2 min association phase followed by a 12 min dissociation phase. For the sandwich binding experiments, approx-
imately 100 resonance units of His-tagged IgE-Fc was captured on an 8D6 Fab surface; after a 2 min stabilization 
period, 8D6 Fab was injected at 30 μL/min with a 2 min association phase followed by a 12 min dissociation phase. 
The sensor surface was regenerated by two 30 sec injections of 0.2 M glycine-HCl, pH 2.3.
For measuring the binding of derCD23 to IgE-Fc or 8D6 Fab-bound IgE-Fc, all experiments were performed 
in HBS-P buffer with 5 mM CaCl2. DerCD23 binding to (1) N-terminally His-tagged IgE-Fc captured using an 
anti-His-tag antibody (Biacore His Capture Kit, GE Healthcare), (2) IgE-Fc captured on an 8D6 Fab surface, 
resulting in derCD23 binding to a 1:1 8D6 Fab/IgE-Fc complex, and (3) IgE-Fc captured on an 8D6 Fab surface, 
and then bound to a second 8D6 Fab by injecting a saturating concentration (100 nM) of 8D6 Fab, resulting in 
derCD23 binding to a 2:1 8D6 Fab/IgE-Fc complex. DerCD23 solutions over a range of concentrations (10, 5, 2.5, 
1.25, 0.625, 0.312, 0.156 and 0 μM) were injected at 20 μL/min with a 60 sec association phase, followed by a 90 sec 
dissociation phase. All measurements were done in duplicate, using titration series of “low-to-high” analyte con-
centration followed by a “high-to-low” series51 at 25 °C. In all cases, standard double referencing data subtraction 
methods were used51 and kinetic fits were performed using Origin software (OriginLab).
Flow cytometry analysis of IgE binding to membrane CD23 on RPMI 8866 cells. To examine the 
effect of 8D6 on IgE binding to membrane CD23, 0.5 × 106 cells from a CD23 expressing cell line (RPMI 8866), 
maintained as described previously52, were incubated with 5 μg/mL of IgE-Fc Alexa-647 with or without 10 μg/mL 
8D6 (anti-IgE). MHM6 (anti-CD23) and omalizumab (anti-IgE), two known inhibitors of IgE binding to CD2347, 
were used as controls. After 30 minutes of incubation on ice, cells were washed by centrifugation at 300 × g for 
5 mins at 4 °C, collected using a BD FACSCanto and analysed using FlowJo software (Tree Star Inc).
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Crystallization. For crystallization trials, the 8D6 Fab was buffer-exchanged into 20 mM Tris-HCl pH 8.6, 
and concentrated to an OD280 of 11. 8D6 Fab crystals were grown by sitting drop vapour diffusion at 18 °C in MRC 
96 well plates. The reservoir contained 50 µL of 0.1 M ADA (N-(2-acetamido) iminodiacetic acid) pH 6.5 and 12% 
(w/v) PEG 4000. The drop contained 250 nL and 400 nL of protein solution and reservoir, respectively. Crystals 
were cryoprotected in 0.1 M Tris-HCl pH 7.0, 20% (w/v) PEG 3350, 0.2 M (NH4)2SO4 and 18% (v/v) ethylene gly-
col before flash-cooling in liquid nitrogen. Purified 8D6 Fab/IgE-Fc complex was buffer-exchanged into 100 mM 
Tris-HCl pH 7.4 and 50 mM NaCl, and concentrated to an OD280 of 16.4. Crystals of the 8D6 Fab/IgE-Fc complex 
were also grown by sitting-drop vapour diffusion. The reservoir contained 75 µL of 0.1 M Tris-HCl pH 8.0 and 
45% (v/v) pentaerythritol propoxylate (5/4PO/OH). The drop contained 100 nL and 50 nL of protein solution 
and reservoir, respectively. Crystals were flash-cooled in liquid nitrogen using mother liquor as a cryoprotectant.
X-ray data collection, structure determination and refinement. Data for the 8D6 Fab were collected 
at beamline I04 at the Diamond Light Source (Harwell, UK). Intensities were integrated with XDS using the xia2 
package53,54, and further processed to 2.4 Å resolution with programs from the CCP4 suite55,56. The structure 
was solved in space group P43, with three Fab molecules in the asymmetric unit. The structure was solved by 
molecular replacement with PHASER57 using protein atoms from PDB entry 1I7Z58 as a search model. Data for 
the 8D6 Fab/IgE-Fc complex were collected at beamline I04-1 at the Diamond Light Source. Intensities were 
integrated with XDS53 and further processed to 3.7 Å resolution with programs from the CCP4 suite55,56. The 
structure was solved in space group P212121, using a combination of molecular replacement with PHASER57 
and manual domain placement, using a partially refined 8D6 Fab structure and protein atoms from PDB entry 
2WQR as search models19, and the asymmetric unit contained one 2:1 8D6 Fab/IgE-Fc complex. Both struc-
tures were refined with PHENIX59. Manual model building was performed with Coot60. Overall structure quality 
was assessed with MolProbity61 and POLYGON62 within PHENIX. Data processing statistics are summarized in 
Table 1. A representative electron density map for each structure is shown in Supplementary Fig. S9. Interfaces 
were analysed with PISA63, figures were produced with PyMOL64, and movies were generated using Chimera65, 
PyMOL64 and the eMovie plugin66 for PyMOL.
Data availability. Coordinates and structure factors have been deposited at the Protein Data Bank with 
accession codes 6EYN (8D6 Fab) and 6EYO (8D6 Fab/IgE-Fc complex).
8D6 Fab 8D6Fab/IgE-Fc complex
Data processing
Space group P 43 P 21 21 21
Unit cell dimensions
a, b, c (Å) 157.96, 157.96, 77.50 119.48, 119.60, 132.99
Resolution (Å) 70.64–2.40 (2.45–2.40)a 88.93–3.70 (4.05–3.70)a
No. of unique reflections 74 039 (4 617)a 20 732 (4 698)a
Completeness (%) 98.8 (99.9)a 98.8 (95.3)a
Multiplicity 6.2 (6.3)a 6.6 (6.8)a
Mean ((I)/σ(I)) 10.5 (1.9)a 6.8 (2.8)a
Rmerge (%) 12.3 (147.6)a 22.4 (69.1)a
Rpim (%) 4.9 (58.1)a 9.4 (28.4)a
CC1/2 0.996 (0.643) 0.989 (0.819)
Refinement
Rwork/Rfree (%)b 18.13/21.21 24.73/28.82
RMSD
Bond lengths (Å) 0.003 0.002
Bond angles (°) 0.643 0.510
Coordinate error (Å) 0.32 0.49
No. of atoms
Proteinc 9 152 10 230
Carbohydrate 0 155
Solvent 249 0
Otherd 59 0
Ramachandran plot
Favoured (%) 96.59 96.21
Allowed (%) 3.33 3.65
Table 1. Data processing and refinement statistics. aNumbers in parentheses are for the highest resolution shell. 
bRfree set comprises 5% of reflections. cIncludes alternative conformations. dEthylene glycol, polyethylene glycol, 
sulphate.
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